United Therapeutics Corporation (NASDAQ: UTHR), a prominent player in the healthcare sector, is making waves with its strong focus on addressing unmet medical needs in the treatment of chronic and life-threatening diseases. As investors consider adding this specialty drug manufacturer to their portfolios, several key factors demand attention.

With a market capitalization of $21.41 billion, United Therapeutics has firmly entrenched itself as a leader in the biotechnology space. The company’s current stock price stands at $473.39, having experienced a marginal decline of 0.01% recently. Despite this slight decrease, the stock’s 52-week range reveals a robust performance, with a low of $274.70 and a high of $517.13, indicating…